CAJ | 학술논문

肝癌(HCC)是全球最富有挑战件的恶性肿瘤之一.HCC需要综合治疗,目前尚无特效的治疗药物.分子靶向药物的发展,使HCC的全身治疗有了新的希望.阐述了分子靶向药物的现状,多激酶抑制剂、抗血管生成和抗表皮生长因子受体药物在临床上的进展,认为索拉芬尼是晚期HCC的新的标准治疗药物.
간암(HCC)시전구최부유도전건적악성종류지일.HCC수요종합치료,목전상무특효적치료약물.분자파향약물적발전,사HCC적전신치료유료신적희망.천술료분자파향약물적현상,다격매억제제、항혈관생성화항표피생장인자수체약물재림상상적진전,인위색랍분니시만기HCC적신적표준치료약물.
It is well appreciated that hepatocellular carcinoma (HCC) represents one of the most challenging malignancies of worldwide importance. HCC is a disease that requires multidisciplinary management. There has been no widely accepted standardard systemic therapy for this disease until recently. However, with the arrival of newly developed, molecularly targeted agents, there has been renewed interest in developing novel systemic therapy in HCC. For this review, the authors concisely summarized the current status of molecular targeted agents: muhikinase inhibitor, antiangiogenesis and anti-EGFR agents, which are under clinical development, focus on new agents with promise, particularly sorafenib, a drug that appear to be the new standard of care for advanced HCC.